Carregant...
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
BACKGROUND: Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine. Galcanezumab demonstrated early onset of effect in patients with migraine but it is unknown whether the same holds true for patients wh...
Guardat en:
| Publicat a: | J Headache Pain |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Milan
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7992932/ https://ncbi.nlm.nih.gov/pubmed/33765912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-021-01230-w |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|